Table 5.

CRPC-specific health care utilization during baseline and follow-up periods

Health care utilization	Oncology cohort (n = 1590) %	Urology cohort (n = 995) %	P-value
Baseline period
Docetaxel use	2.64	0.60	<0.001
Inpatient stay	9.43	4.12	<0.001
ER visit	13.77	14.47	0.619
Ambulatory visit	98.93	95.48	<0.001
Variable follow-up period
Docetaxel use	38.24	7.04	<0.001
Inpatient stay	35.72	12.16	<0.001
ER visit	33.58	34.87	0.328
Ambulatory visit	97.99	93.07	<0.001

Abbreviations: CRPC, castration-resistant prostate cancer; ER, emergency room.